EU Calls For Suspension Of J&J's Ionsys

Law360, New York (November 20, 2008, 12:00 AM EST) -- In a blow to Johnson & Johnson, the European Union's drug-regulating body has recommended suspending approval for the sale of Ionsys in Europe because of a defect with the pain medicine's delivery system that could cause overdoses.

The European Medicines Agency's Committee for Medicinal Products for Human Use said Thursday it made the decision after J&J unit Janssen-Cilag International NV – which markets Ionsys in Europe – informed the CHMP that it had detected corrosion of a component of the system in one batch of the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.